Pharmacoeconomic evaluation of antidepressant therapies.
With today's emphasis in the managed care environment on evidentiary literature, new antidepressants must provide economic evidence of their value compared with previously available agents. Various pharmacoeconomic models have shown newer antidepressant agents to be cost-effective relative to older agents. The authors review methodologies and published results.